Navigation Links
Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
Date:1/24/2010

d neutropenia; complications were rare, with only 1 patient (2 percent) having febrile neutropenia and 2 patients (4 percent) having minor bleeding issues.
  • Most other toxicities, including gastrointestinal toxicity, were similar for both regimens except for alopecia, which was more frequent with FOLPI.

  • About Picoplatin

    Picoplatin is a new and differentiated platinum-based chemotherapeutic agent that is in clinical development for multiple cancer indications, treatment combinations and by two routes of administration.  It is designed to overcome platinum resistance associated with chemotherapy in solid tumors.  Study data to date suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies and can be safely administered in combination with multiple approved oncology products.  Approximately 1,100 patients have received picoplatin.  Results obtained to date suggest that hematologic events are common but manageable.  Kidney toxicity (nephrotoxicity) and nerve toxicity (neurotoxicity) are less frequent and less severe than is commonly observed with other platinum chemotherapy drugs.  Picoplatin has demonstrated anti-tumor activity in a variety of solid tumors.

    In addition to the Phase 2 clinical trial of picoplatin in patients with metastatic CRC, Poniard has evaluated intravenous picoplatin in the treatment of small cell lung cancer in its Phase 3 SPEAR trial.  This trial did not meet its primary endpoint of overall survival, and the Company plans to meet with the FDA to discuss a potential regulatory path forward for picoplatin in this indication.  Poniard is also evaluating picoplatin in a Phase 2 clinical trial in patients with metastatic hormone-refractory prostate cancer.  Final results of the Company's Phase 1 cardiac safety trial and the Phase 1 trial of an oral formulation of picoplatin were presented in
    '/>"/>

    SOURCE Poniard Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
    2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
    3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
    4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
    5. Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
    6. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
    7. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
    8. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
    9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
    10. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
    11. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/10/2014)... , July 10, 2014   Ventana Medical Systems, ... announced it has entered into an agreement with Merck ... as EMD Serono in the United States ... collaborate with Merck KGaA,s biopharmaceutical division on the development ... undisclosed target using Ventana,s proprietary diagnostic assays. In alignment ...
    (Date:7/10/2014)... WOONSOCKET, R.I. , July 10, 2014 CVS ... its board of directors has approved a quarterly dividend of ... The dividend is payable on August 1, 2014, to holders ... Caremark CVS Caremark is dedicated to helping ... integrated pharmacy company in the United States ...
    (Date:1/15/2014)... 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds "China Orthopedic Instrument Industry ... (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ) Benefiting ... China,s orthopedic instrument industry has ... size rising from 3.28 billion yuan in 2006 to ...
    Breaking Medicine Technology:Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3
    ... , REDWOOD CITY, Calif., July 22 ... the full results of the PAS-Port system multi-center pivotal trial, known ... the peer-reviewed publication The J ournal of Thoracic and ... from the U.S. Food and Drug Administration (FDA) in September 2008, ...
    ... , , SOUTH SAN FRANCISCO, ... ), a biopharmaceutical company focused on innovative oncology therapies, today announced ... new generation platinum-based chemotherapy agent and the Company,s lead product candidate. ... (FDA) to design this study, which is required for new chemical ...
    Cached Medicine Technology:Cardica Announces Publication of Pivotal PAS-Port(R) Proximal Anastomosis System Clinical Trial Results 2Cardica Announces Publication of Pivotal PAS-Port(R) Proximal Anastomosis System Clinical Trial Results 3Cardica Announces Publication of Pivotal PAS-Port(R) Proximal Anastomosis System Clinical Trial Results 4Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing 2Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing 3
    (Date:7/11/2014)... 11, 2014 Riverside Health System became the ... in Virginia in late 2012 and now, in partnership with ... residents throughout the Williamsburg and Newport News region. , Also ... and benefits to independent older adults who wish to remain ... safety net of continuing care services as well as control ...
    (Date:7/11/2014)... Europe is one of the largest consumers of micro ... area. The agricultural sector is a significant user of ... the total water use. The scale and importance of ... far from negligible in most northern ones. , In ... the water use in most countries, while in the ...
    (Date:7/11/2014)... July 11, 2014 Pigments are insoluble ... mainly three functions namely protective coating, opacity, and coloring. ... materials that impart color to substances such as paper, ... the pigments, which upon application impart color to the ... oxide, carbon black, and hematite. , The coloring action ...
    (Date:7/11/2014)... the best available treatment for patients, from a range ... for taxpayers than the existing clinical trial process, a ... carried out while he was a member of the ... based at The University of Manchester,s Health eResearch Centre, ... ) today (Friday 11 July) looked at the use ...
    (Date:7/11/2014)... Mexico (PRWEB) July 11, 2014 Experience ... the Mayan Heritage Experience Package at the luxury all-inclusive ... the package include a guided on-site ecological family tour ... well as The Coba Mayan Encounter Tour at the ... Nohoch Muul, the tallest pyramid in the Yucatan and ...
    Breaking Medicine News(10 mins):Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 2Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 3Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 4Health News:Europe Micro Irrigation System Market Driven by Growing Environmental Concerns and Decreasing Water Availability - New Report by MicroMarket Monitor 2Health News:Europe Micro Irrigation System Market Driven by Growing Environmental Concerns and Decreasing Water Availability - New Report by MicroMarket Monitor 3Health News:Americas Pigments Market Worth 1,099 Thousand MT by 2018 - New Report by MicroMarket Monitor 2Health News:Americas Pigments Market Worth 1,099 Thousand MT by 2018 - New Report by MicroMarket Monitor 3Health News:Better use of electronic health records makes clinical trials less expensive 2Health News:Explore the Aura and Mystery of the Yucatan’s Mayan Culture with New Hotel Package at AAA Five Diamond Grand Velas Riviera Maya 2Health News:Explore the Aura and Mystery of the Yucatan’s Mayan Culture with New Hotel Package at AAA Five Diamond Grand Velas Riviera Maya 3
    ... , SHENZHEN, China, Dec. 22 /PRNewswire-FirstCall/ - Hard to ... that it has an agreement in principle to sell its ... in China. The buyer, founded in 2004, focuses on production ... Name of the buyer will be announced in a joint ...
    ... lifestyle on top of genetics , TUESDAY, Dec. 22 (HealthDay ... take an additional toll on sun-damaged skin, a new study ... Western Reserve Medical School in Cleveland, suggest that "people with ... same sort of sun damage," said Dr. Jonette Keri, an ...
    ... the University of Central Florida have found a protein that ... common and aggressive brain tumors in adults. Glioblastoma multiforme ... late U.S. Sen. Edward Kennedy, is difficult to treat because ... very quickly. About 10,000 cases are diagnosed in the United ...
    ... the hemophilia mutation that affected Queen Victoria and her European ... Able to trace rare genetic disease mutations, the tool can ... Now, Tel Aviv University has its own deep sequencer ... Analyzer housed in a new Genome Facility. The tool ...
    ... in Canada are reporting the development of a fast, ... that may exist in foods and beverages. Their paper-strip ... results in minutes rather than hours by means of ... published in ACS, Analytical Chemistry , a semi-monthly ...
    ... , , ATLANTA, Dec. ... the market leader in automated revenue integrity solutions that improve ... the rank of first in the Revenue Cycle - Chargemaster ... KLAS Awards: Software & Professional Services" report, published December 2009. ...
    Cached Medicine News:Health News:Hard to treat Diseases (HTDS) To Sell Its MindUp BioResearch Division 2Health News:Hard to treat Diseases (HTDS) To Sell Its MindUp BioResearch Division 3Health News:Hard to treat Diseases (HTDS) To Sell Its MindUp BioResearch Division 4Health News:Sun, Smoke, Extra Weight Add Years to Skin 2Health News:Sun, Smoke, Extra Weight Add Years to Skin 3Health News:Adding a genetic supertool 2Health News:Craneware's Chargemaster Toolkit(R) Earns #1 KLAS Rank for Fourth Consecutive Year 2Health News:Craneware's Chargemaster Toolkit(R) Earns #1 KLAS Rank for Fourth Consecutive Year 3
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    Medicine Products: